This article reviews recent and ongoing developments in multiparametric magnetic resonance imaging (mpMRI) of the prostate.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
Advances in T2-weighted imaging, diffusion-weighted imaging, dynamic contrast-enhanced imaging, and spectroscopic imaging are described along with advances related to radiofrequency coils and imaging at high magnetic field. As mpMRI is increasingly becoming routine in various aspects of clinical prostate cancer management, its role in detection, localization, staging, assessment of aggressiveness, and active surveillance is discussed. Combined with growing clinical adoption of the techniques already at hand, continual optimization of acquisition techniques and image interpretation schemes will further strengthen the role of mpMRI as an important diagnostic test in prostate cancer management.
Scheenen TW, Rosenkrantz AB, Haider MA, Fütterer JJ. Are you the author?
Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands; Department of Radiology, NYU Langone Medical Center, New York, NY; Department of Medical Imaging, Sunnybrook Health Sciences Centre; and University of Toronto, Toronto, Canada.
Reference: Invest Radiol. 2015 May 13. Epub ahead of print.